Кантузумаб равтансин

C₆₅₇₀H₁₀₁₃₀N₁₇₂₆O₂₀₁₈S₄₄(C₄₂H₅₉ClN₃O₁₁S₂)n

• Химическое название: immunoglobulin G1-kappa, anti-[Homo sapiens MUC1 sialylated carbohydrate, tumour-associated (CA242, cancer antigen 242)], humanized monoclonal antibody conjugated to maytansinoid DM4;
  gamma1 heavy chain (1-449) [humanized VH (Homo sapiens IGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-449)], (222- 219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV2-28*01 (82.00%) -IGKJ3*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; (228-228":231-231")-bisdisulfide dimer ; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM4 [N²'-deacetyl-N²'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine] via the reducible SPDB linker [N-succinimidyl 4-(2-pyridyldithio)butanoate]
• Drugbank: DB05594
• CAS: 868747-45-9
• Структура

Информация о действующем веществе Кантузумаб равтансин предназначена для медицинских и фармацевтических специалистов, исключительно в справочных целях.